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Abstract Residues considered essential for ATP binding to the
human P2X7 receptor (hP2X7R) were investigated. HEK293
cells or Xenopus oocytes were transfected with wild-type or site-
directed mutants of hP2X7R constructs and channel/pore activity
measured in the presence of ATP or 2P,3P-O-(4-benzoylbenzoyl)-
ATP (BzATP). Barium uptake and ethidium influx into HEK293
cells were abolished in cells expressing K193A and K311A
mutants, and were partially reduced in cells expressing mutant
P210A. K193A and K311A mutations also completely abolished
responses to ATP and BzATP in Xenopus oocytes as measured
by electrophysiology. These results indicate that K193 and K311
are essential residues in ATP binding in the hP2X7R. ß 2002
Published by Elsevier Science B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Extracellular ATP is a ubiquitous signaling molecule that
exerts its e¡ects by binding to a family of P2X receptors,
designated P2X1ÿ7, which are fast, ligand-gated cation chan-
nels. These subtypes exhibit extensive homology (30^40%) but
di¡er considerably in the length of their carboxy-termini. The
long intracellular C-terminus is unique to P2X7, and is
thought to confer time-dependent dilation of the channel to
form a pore [1]. Three polymorphisms have been identi¢ed in
the P2X7 gene that alters the primary structure of the receptor
[2]. One of these at position 496 in the carboxy-terminal tail
leads to loss of the permeability properties of P2X7 for both
small inorganic cations and large organic cations [3]. The
functional e¡ects of the common polymorphisms at positions
155 and 348 have not been reported.
There have been few studies of the residues in the extracel-
lular domain that are critical for agonist binding to P2X7.
Positively charged amino acids, such as lysine, have been
shown to be important in ATP binding by interacting with
the phosphate groups of the ATP molecule. In the extracellu-
lar loop of the P2X receptors, there are seven conserved ly-
sines. Mutation at two of these in hP2X1, K70 and K309,
decreased the potency of ATP by many orders of magnitude
[4]. In rP2X2, mutation at K69 and K188 also decreased the
potency of ATP, and mutation at K308 abolished the re-
sponse [5]. The exact location of the ATP binding pocket in
human P2X7 receptor (hP2X7R) is uncertain, though many
studies of the P2X7 purinoceptor indicate a cooperative pro-
cess in pore opening, suggested by Hill coe⁄cients of approx-
imately two observed for mast cells and thymocytes [6,7], and
hP2X7R expressed in Xenopus oocytes [8] and studies indicate
that the increment in permeant £ux shows a sigmoid depen-
dence on ATP concentration. This cooperative e¡ect of ATP
in stimulating permeant in£ux is consistent with ATP binding
to multiple sites on an oligomeric channel to initiate opening.
In one study on P2X7 receptors, residue 214 was associated
with an ATP binding site based on marked species di¡erences
in agonist dissociation rates between rat, mouse and human
P2X7 [9].
In the present study de novo protein design was utilized to
determine if two of the seven conserved lysine residues in the
extracellular loop of P2X7 were critical sites for nucleotide
binding. A proline residue downstream of the ¢rst identi¢ed
lysine was also targeted to examine agonist potency at the
putative binding site. Furthermore, two polymorphic changes,
H155Y and A348T, identi¢ed in human population studies of
P2X7 [2], also were tested. Since truncation of the carboxy-
terminal tail of the rat P2X7 receptor (rP2X7R) inhibits pore
but not channel properties [10], a C-terminal truncated
hP2X7R was investigated.
2. Materials and methods
2.1. Materials
ATP, 2P,3P-O-(4-benzoylbenzoyl)-ATP (BzATP), ethidium bromide,
barium chloride, RPMI 1640 medium, D-glucose, BSA (bovine serum
albumin), and FluoroTag FITC Conjugation Kit were obtained from
Sigma (St. Louis, MO, USA); Ficoll-Hypaque (density 1.077), GFX1
PCR DNA and Gel Band Puri¢cation Kit from Amersham Pharma-
cia (Uppsala, Sweden); Cy2-conjugated anti-mouse Ig antibody from
Jackson ImmunoResearch (West Grove, PA, USA); A⁄Gel 10 from
Bio-Rad (Hercules, CA, USA); HEPES, Lipofectamine1 2000 re-
agent, Taq DNA polymerase, Opti-MEM I medium from Life Tech-
nologies (Gaithersburg, MD, USA); The Wizard Genomic DNA
Puri¢cation Kit from Promega (Madison, WI, USA); QIAquick Gel
Extraction Kit from Qiagen (Australia); QuikChange1 Site-Directed
Mutagenesis Kit from Stratagene (La Jolla, CA, USA); and mMes-
sage mMachine kit mRNA from Ambion (Austin, TX, USA).
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2.2. Tissue culture
HEK293 cells were transfected with cDNAs encoding human or
one of six mutant constructs of P2X7 receptors using Lipofectamine
2000. Cells were maintained in RPMI 1640 complete medium supple-
mented with 10% heat-inactivated fetal calf serum, 2 mM glutamine,
and 0.02 mg/ml gentamicin at 37‡C, 5% CO2.
2.3. Site-directed mutagenesis
The full-length clone of hP2X7 (GenBank accession number
Y09561) was prepared as described [3]. The QuikChange1 Site-
Directed Mutagenesis Kit (Stratagene) was used according to the
manufacturer’s instructions to perform point mutations in the
hP2X7Rs.






















Base changes introducing the mutations are in bold type. Truncated
hP2X7 (1^415) in pcDNA 3 (Invitrogen) was provided by Dr. G.
Buell. Site-directed mutations were con¢rmed by sequence analysis.
2.4. Xenopus oocyte in vitro RNA preparation
The in vitro RNA preparation protocol used was as described [11].
2.5. Measurement of ATP-evoked currents in Xenopus oocytes by
two-electrode voltage clamp
Oocytes were prepared from adult female Xenopus laevis (Disa Ex-
porters, Somerset West Cape, South Africa) using standard proce-
dures. Stage 5 or 6 oocytes were injected with approximately 50 ng
of cRNA; hP2X7 wild-type and human mutants K193A or K311A.
Injected oocytes were stored at 18‡C for 2 days before functional
assay. Oocytes were impaled with two glass electrodes containing
3 M KCl and were clamped at a membrane potential of 370 mV
using an Axoclamp 2B ampli¢er. Oocytes were perfused (2 ml/min)
with a low divalent ND96 solution (96 mM NaCl, 2 mM KCl, 0.1 mM
BaCl2, 5 mM HEPES, pH 7.5). ATP or BzATP was applied for 15 s
or until a peak current was recorded. Any additional doses of ATP
were applied after a 20 min washout period. All electrical recordings
were carried out at room temperature (20^22‡C).
2.6. P2X7 transfection of HEK293 cells
HEK293 cells do not natively express any of the known P2X re-
ceptor subtypes at sub-con£uence, allowing for the expression of the
P2X7R as a homomeric receptor in this cell type. However, on reach-
ing over-con£uence HEK293 cells express P2X1ÿ6 [12] as well as P2X7
(unpublished results). Truncated, germline and mutant pCI-P2X7
plasmids were transfected into HEK293 cells as described [3].
2.7. Immuno£uorescent staining
Immuno£uorescent staining and confocal microscopy of HEK293
cells incubated on collagen-coated glass coverslips was performed as
described [13] using a P2X7 polyclonal antibody [14]. Anti-human
P2X7R monoclonal antibody clones L4 and B2 were prepared as
described [3,15].
2.8. Ethidium in£ux measurement by £ow cytometry
Flow cytometry was used to quantitate ethidium bromide uptake as
described [16].
3. Results
3.1. Surface expression of P2X7 constructs in transiently
transfected HEK293 cells
Confocal microscopy showed wild-type P2X7 (Fig. 1a) and
mutants P210A (Fig. 1d), K193A (Fig. 1e), K311A (Fig. 1f)
expressed equally strongly on the surface of HEK293 cells
where they were labeled using Cy3 bound to a polyclonal
P2X7 antibody. Negative controls included untransfected cells
(Fig. 1b) and wild-type in the presence of 10 WM adsorption
control peptide epitope (Fig. 1c). The extracellular epitope on
Fig. 1. Confocal microscope images of human and mutant P2X7R
expression on the surface of HEK293 cells. HEK293 cells transiently
transfected with either (a) wild-type, (b) untransfected control,
(c) wild-type epitope block, (d) P210A, (e) K193A, (f) K311A,
(g) truncated or (h) permeabilized cells with truncated P2X7 cDNA
were labeled with antibody against P2X7 and subsequently with
Cy3-conjugated anti-rabbit IgG antibody. Non-transfected cells were
included as a negative control and showed no staining. The calibra-
tion bar is 4 Wm.
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the C-terminal truncated protein was unlabeled (Fig. 1g) un-
less cells were permeabilized (Fig. 1h) indicating the truncated
mutant could not insert into the cell membrane. Identical
results were obtained using anti-P2X7 monoclonal antibodies
(data not shown).
3.2. Functional analysis of pore formation of P2X7R constructs
by ATP-induced uptake of ethidium and Ba2+
Uptake of the £uorescent dye ethidium measured by £ow
cytometry was used as an indicator of the £ux of a larger
permeant through the P2X7 pore. ATP did not stimulate
ethidium uptake in untransfected HEK293 cells. ATP pro-
duced an eight-fold increase in the rate of ethidium in£ux in
cells transiently transfected with wild-type hP2X7, H155Y and
A348T cDNA. ATP-induced ethidium uptake was abolished
in cells expressing mutants K193A or K311A receptors (see
Fig. 2). Cells expressing mutant P210A elicited a reduced re-
sponse compared with wild-type. Fluorometry was used to
examine the entry of Ba2 via the P2X7 channel in cells
loaded with Fura-2 [17]. ATP-induced Ba2 in£ux was mea-
sured in cells transfected with the P2X7 constructs and incu-
bated in both HEPES-bu¡ered KCl bu¡er and sucrose bu¡er.
Identical results were obtained for all constructs using £uo-
rometry as for £ow cytometry. ATP was unable to induce
Ba2 uptake in cells transfected with the K193A and K311A
mutants, with the P210A mutant attenuating Ba2 uptake
compared to wild-type hP2X7R, in HEPES-bu¡ered KCl
bu¡er. Both wild-type and P210A hP2X7R demonstrated rel-
atively increased Ba2 uptake in sucrose bu¡er due to the
removal of extracellular Cl3 ions, as previously reported for
wild-type P2X7R [18]. However, neither the K193A or K311A
mutants showed Ba2 uptake in the Cl3-free sucrose bu¡er
(data not shown).
3.3. Expression of hP2X7 mutants in Xenopus oocytes
As expected from rP2X7 [11], expression of wild-type
hP2X7 resulted in robust ATP-activated inward current while
sham-injected oocytes gave no response. Introduction of
K193A and K311A mutations completely abolished receptor
responses to ATP (Fig. 3).
In oocytes expressing wild-type hP2X7R, BzATP elicited
greater responses than ATP and the recovery of current to
baseline following BzATP was signi¢cantly longer than for
ATP (BzATP 5.8 þ 1.6 min, n = 3 vs. ATP 2.0 þ 1.1 min, n = 4). BzATP, like ATP, was without e¡ect on oocytes in-
jected with K193A and K311A hP2X7R cRNA (Fig. 3).
ATP and BzATP sensitivity of wild-type P2X7R expressed
in Xenopus oocytes was determined from dose^response
curves. Considerable care was taken to ensure adequate time
had elapsed (20 min) between subsequent doses of agonists to
ensure receptors were not desensitized. Data were only used
where at least two responses to the same concentration of
agonist produced identical currents as a measure of recovery
from any desensitization.
Consistent with earlier work, sensitivity of wild-type
hP2X7R to BzATP was signi¢cantly greater than to ATP
[10,19,20] with EC50 of 46 WM and 23 WM and Hill coe⁄cients
of 1.96 and 2.14 (n = 4) for ATP and BzATP respectively (data
not shown).
4. Discussion
Positively charged residues usually contribute to binding K
Fig. 2. ATP-induced ethidium uptake into transiently transfected
HEK293 cells. Mean channel £uorescence intensity measured over
5 s intervals for wild-type, P210A, K193A or K311A P2X7.
Fig. 3. Comparison of response to ATP and BzATP in wild-type
and mutant hP2X7Rs expressed in Xenopus oocytes. Application of
100 WM ATP or 3 WM BzATP induced a rapid inward current in
wild-type hP2X7-injected oocytes, with sensitivity to BzATP signi¢-
cantly greater than to ATP. No agonist-induced current was ob-
served in oocytes injected with K193A or K311A hP2X7 cRNA.
Saturation of the P2X7R constructs with supramaximal concentra-
tions of ATP (1000 WM) or BzATP (30 WM) signi¢cantly prolonged
recovery of current to baseline for wild-type P2X7, but still failed to
elicit a response for K193A or K311A mutants.
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and Q phosphates of ATP, and these are usually lysine [21,22].
The present study shows removing the positive charge by
substituting alanine for lysine at 193 and 311 abolished
ATP-induced uptake of both small and large cation perme-
ants.
These lysines are conserved throughout the P2X receptor
family, and recent studies on hP2X1 [4] and rP2X2 [5] recep-
tors suggest these lysines contribute to phosphate binding.
Residues homologous to K311 in P2X1 and P2X2 exhibit total
knockout of function when mutated in P2X7. Mutating K193
to A in P2X7 also results in total knockout of function, while
in P2X2 the e¡ect is more muted and in P2X1 the e¡ect is
further reduced, in line with an associated increase in ATP
binding strength, with EC50s of 100, 10 and 1 WM respectively
[23]. Moreover, the observed e¡ect on channel function cor-
relates with the pore-forming phenotype of the three di¡erent
receptor subtypes after continued exposure to agonist. P2X7
forms pores much more capably than P2X2, while P2X1 ap-
pears unable to form pores.
Pro210 is conserved in mouse, rat and human P2X7 sequen-
ces. Studies on the P210A mutant using £uorometry and £ow
cytometry indicated a partial reduction in receptor function
compared with wild-type. P210 lies between K193, which we
have shown is involved in an ATP binding site, and position
214. Replacement of the isoleucine at residue 214 is known to
a¡ect dissociation of agonist binding [9] and therefore a¡ects
the potency of ATP, indicating 214 lies in an ATP binding
site. The P210A mutant attenuates hP2X7 function, but is not
imperative for binding of ATP. It is possible that agonist
potency in the P210A mutant is a¡ected through an increase
in ATP dissociation resulting in a shorter pore opening time
as evidenced by reduced ethidium uptake.
We found no evidence that truncated hP2X7 (1^415) ex-
pressed on the surface of HEK293 cells since the extracellular
epitopes were not accessible to our extracellular antibody
(Fig. 1g,h). This suggests the C-terminal tail of hP2X7R is
essential for tra⁄cking the receptor to the cell surface, in
contrast with rP2X7R, the truncated form of which tra⁄cs
to the cell surface and forms functional channels in
HEK293 cells [10]. Truncated hP2X7R (1^439) expresses on
the surface of Xenopus oocytes because currents are obtained
[8]. This suggests segment 416^439 is essential for tra⁄cking,
or that there are signi¢cant di¡erences in tra⁄cking responses
between amphibian and mammalian expression systems.
There have been few studies of the residues in the extracel-
lular domain that are critical for agonist binding to P2X7 or
the stoichiometry of this binding. We have shown that P210A
attenuates but does not abolish full function of the receptor,
and that lysines K193 and K311 in hP2X7R are essential for
ATP-induced channel and pore in£ux; whether they bind
ATP phosphates in one site, or contribute to two di¡erent
ATP binding sites within an oligomeric hP2X7R, remains to
be determined.
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